RESUMEN
PURPOSE: To evaluate the rate, the histological spectrum and the positive predictive value (PPV) for malignancy of minimally invasive biopsies with "uncertain malignant potential (B3)" in digital mammography screening. METHODS AND MATERIALS: Consecutive data of 37,178 participants of one digital unit of the German screening program were included. RESULTS: The B 3 rate was 15.1 % (148 / 979). The frequencies of lesion subtypes were as follows: atypical epithelial proliferation of ductal type (AEPDT) 35.1 % (52 / 148), radial scar (RS) 28.4 % (42 / 148), papillary lesions (PAP) 20.3 % (30 / 148), lobular carcinoma in situ 8.8 % (13 / 148), flat epithelial atypia 5.4 % (8 / 148), and mucocele-like lesions 2.0 % (3 / 148). The PPV for malignancy in surgical excisions was overall 0.28 (25 / 91); in detail 0.40 (19 / 47) for AEPDT, 0.20 (5 / 25) for RS, 0.08 (1 / 12) for PAP. CONCLUSION: Despite a higher B 3 rate of minimally invasive biopsies with "uncertain malignant potential" in digital screening, the benign surgical biopsy rate is not disproportionally increased compared with analog screening programs. Together with defined management protocols, this results in an increased cancer detection rate per screening participant with surgical excision.
Asunto(s)
Biopsia con Aguja/métodos , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/patología , Carcinoma Intraductal no Infiltrante/patología , Carcinoma Lobular/patología , Mamografía/métodos , Tamizaje Masivo , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Papiloma/patología , Intensificación de Imagen Radiográfica/métodos , Anciano , Mama/patología , Enfermedades de la Mama/patología , Calcinosis/patología , Transformación Celular Neoplásica/patología , Diagnóstico Diferencial , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Sensibilidad y EspecificidadRESUMEN
OBJECTIVE: Physicians commonly consider the presence of all differential diagnoses simultaneously. Polytomous logistic regression modeling allows for simultaneous estimation of the probability of multiple diagnoses. We discuss and (empirically) illustrate the value of this method for diagnostic research. STUDY DESIGN AND SETTING: We used data from a study on the diagnosis of residual retroperitoneal mass histology in patients presenting with nonseminomatous testicular germ cell tumor. The differential diagnoses include benign tissue, mature teratoma, and viable cancer. Probabilities of each diagnosis were estimated with a polytomous logistic regression model and compared with the probabilities estimated from two consecutive dichotomous logistic regression models. RESULTS: We provide interpretations of the odds ratios derived from the polytomous regression model and present a simple score chart to facilitate calculation of predicted probabilities from the polytomous model. For both modeling methods, we show the calibration plots and receiver operating characteristics curve (ROC) areas comparing each diagnostic outcome category with the other two. The ROC areas for benign tissue, mature teratoma, and viable cancer were similar for both modeling methods, 0.83 (95% confidence interval [CI]=0.80-0.85) vs. 0.83 (95% CI=0.80-0.85), 0.78 (95% CI=0.75-0.81) vs. 0.78 (95% CI=0.75-0.81), and 0.66 (95% CI=0.61-0.71) vs. 0.64 (95% CI=0.59-0.69), for polytomous and dichotomous regression models, respectively. CONCLUSION: Polytomous logistic regression is a useful technique to simultaneously model predicted probabilities of multiple diagnostic outcome categories. The performance of a polytomous prediction model can be assessed similarly to a dichotomous logistic regression model, and predictions by a polytomous model can be made with a user-friendly method. Because the simultaneous consideration of the presence of multiple (differential) conditions serves clinical practice better than consideration of the presence of only one target condition, polytomous logistic regression could be applied more often in diagnostic research.
Asunto(s)
Técnicas de Apoyo para la Decisión , Diagnóstico Diferencial , Modelos Logísticos , Antineoplásicos/uso terapéutico , Interpretación Estadística de Datos , Humanos , Masculino , Neoplasia Residual , Neoplasias Retroperitoneales/diagnóstico , Neoplasias Retroperitoneales/secundario , Teratoma/diagnóstico , Teratoma/tratamiento farmacológico , Teratoma/secundario , Neoplasias Testiculares/tratamiento farmacológicoRESUMEN
Transgenic mice (G93A) carrying the human amyotrophic lateral sclerosis (ALS) linked superoxide dismutase 1 (SOD1) mutations develop a motoneuron disease resembling human ALS. The affected motoneurons are characterized by the presence of cellular alterations. The antigen recognized by the monoclonal antibody Py is suggested to be associated with the neurofilamentous and microtubular elements of the cytoskeleton of specific neuron populations including the spinal motoneurons. The aim of the present study was to measure changes in the relative Py-immunoreactivity per identified Choline-Acetyl-Transferase (ChAT)-immunoreactive motoneuron during the disease progression. The relative Py-immunoreactivity of identified spinal motoneurons was measured on double stained (Py and ChAT) motoneurons using a digital imaging system coupled to an inverse microscope. A significant decrease of Py-immunoreactivity was already noted in the pre-symptomatic stages of the disease even before the onset of massive motoneuron degeneration. It is concluded that the Py-antibody detects early intracellular abnormalities related to neurodegenerative changes in spinal motoneurons of transgenic SOD1-(G93A) mice.